Literature DB >> 20467775

A case of adalimumab-associated interstitial pneumonia with rheumatoid arthritis.

Hayato Yamazaki1, Susumu Isogai, Tetsushi Sakurai, Kenji Nagasaka.   

Abstract

A 64-year-old woman with rheumatoid arthritis (RA) began to complain of recurrent non-productive cough 5 months after starting adalimumab. The chest radiograph and high-resolution computed tomographic findings revealed diffuse ground-glass attenuation. Her clinical course suggested that interstitial pneumonia (IP) may have been induced by adalimumab, and she was successfully treated with a medium dose of corticosteroid. This case indicates that adalimumab-associated IP should be considered if a RA patient develops non-productive cough following adalimumab therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20467775     DOI: 10.1007/s10165-010-0308-4

Source DB:  PubMed          Journal:  Mod Rheumatol        ISSN: 1439-7595            Impact factor:   3.023


  11 in total

Review 1.  Comprehensive review of current diagnostic and treatment approaches to interstitial lung disease associated with rheumatoid arthritis.

Authors:  Cemal Bes
Journal:  Eur J Rheumatol       Date:  2018-07-01

Review 2.  Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review.

Authors:  Kundan Iqbal; Clive Kelly
Journal:  Ther Adv Musculoskelet Dis       Date:  2015-12       Impact factor: 5.346

3.  Adalimumab-induced interstitial pneumonia in a patient with Crohn's disease.

Authors:  María José Casanova; María Chaparro; Claudia Valenzuela; Carolina Cisneros; Javier P Gisbert
Journal:  World J Gastroenterol       Date:  2015-02-21       Impact factor: 5.742

Review 4.  Interstitial lung disease in patients with rheumatoid arthritis: spontaneous and drug induced.

Authors:  Robert W Hallowell; Maureen R Horton
Journal:  Drugs       Date:  2014-03       Impact factor: 9.546

Review 5.  Noninfectious interstitial lung disease during infliximab therapy: case report and literature review.

Authors:  Roberta Caccaro; Edoardo Savarino; Renata D'Incà; Giacomo Carlo Sturniolo
Journal:  World J Gastroenterol       Date:  2013-08-28       Impact factor: 5.742

6.  Adalimumab (Humira) induced acute lung injury.

Authors:  Ritesh Kohli; Karim Namek
Journal:  Am J Case Rep       Date:  2013-05-27

Review 7.  The safety of biologic therapies in RA-associated interstitial lung disease.

Authors:  Meghna Jani; Nik Hirani; Eric L Matteson; William G Dixon
Journal:  Nat Rev Rheumatol       Date:  2013-12-24       Impact factor: 20.543

Review 8.  Management of Rheumatoid Arthritis Patients with Interstitial Lung Disease: Safety of Biological Antirheumatic Drugs and Assessment of Pulmonary Fibrosis.

Authors:  Shunsuke Mori
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2015-09-08

9.  Adalimumab-induced acute interstitial lung disease in a patient with rheumatoid arthritis.

Authors:  Olívia Meira Dias; Daniel Antunes Silva Pereira; Bruno Guedes Baldi; André Nathan Costa; Rodrigo Abensur Athanazio; Ronaldo Adib Kairalla; Carlos Roberto Ribeiro Carvalho
Journal:  J Bras Pneumol       Date:  2014 Jan-Feb       Impact factor: 2.624

Review 10.  Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Lights and Shadows.

Authors:  Giulia Cassone; Andreina Manfredi; Caterina Vacchi; Fabrizio Luppi; Francesca Coppi; Carlo Salvarani; Marco Sebastiani
Journal:  J Clin Med       Date:  2020-04-10       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.